(Reuters) -The U.S. Food and Drug Administration has approved BridgeBio’s drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer’s blockbuster Vyndaqel.
The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail.
BridgeBio plans to price the therapy at $18,759.12 for a 28-day supply. Pfizer’s Vyndaqel is sold at a list price of $225,000 a year for a recommended once-daily dose of 80 milligrams.
The condition, ATTR-CM, causes difficulty for the heart to pump blood to other parts of the body and causes it to fail if left untreated. It affects more than 120,000 U.S. adults, according to non-profit researcher Institute for Clinical and Economic Review.
Pfizer’s tafamidis capsules, sold as Vyndaqel and Vyndamax, were approved in 2019 and brought in sales of $3.32 billion in 2023.
(Reporting by Chandni Shah, Mariam Sunny and Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar, Sandra Maler and Diane Craft)
Comments